Intrexon reported $1.26M in Cost of Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Agenus AGEN:US USD 7.69M 7.38M
Amgen AMGN:US USD 1.75B 159M
Anika Therapeutics ANIK:US USD 15.49M 1.99M
AstraZeneca AZN:LN USD 2.51B 393M
Bristol Myers Squibb BMY:US USD 2.52B 167M
Gilead Sciences GILD:US USD 1.4B 1000K
GlaxoSmithKline GSK:LN GBP 2.18B 209M
Heron Therapeutics HRTX:US USD 14.72M 1.46M
Intrexon XON:US USD 1.26M 320K
Karyopharm Therapeutics KPTI:US USD 1.87M 888K
Ligand Pharmaceuticals LGND:US USD 21.61M 7.46M
MacroGenics MGNX:US USD 1.79M 1.35M
Mannkind MNKD:US USD 16.12M 1.34M
Merk MRK:US USD 3.36B 519M
Novartis NOVN:VX USD 3.84B 180M
Peregrine Pharmaceuticals PPHM:US USD 28.19M 2.42M
Rigel Pharmaceuticals RIGL:US USD 342K 92K
Roche Holding ROG:VX 8.95B 613M
Thermo Fisher Scientific TMO:US USD 6.72B 340M
Veracyte VCYT:US USD 26.83M 823K
YTE INCY:US USD 53.76M 4.48M